MAMunisa Atoeva

Munisa Atoeva

*This is an algorithmically generated author record based on publicly available information.

Munisa Atoeva has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Guzal Abdullaeva

    Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии

    2 shared publications
  • Iroda Ibragimova

    Республиканского Специализированного Научно-практического Медицинского Центра Кардиологии

    1 shared publication
  • Xafiza Yusupova

    Respublika ixtisoslashtirilgan ilmiy-amaliy kardiologiya tibbiyot markazi

    1 shared publication
  • В Мансурова

    Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии

    1 shared publication
  • Г Хамидуллаева

    Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии

    1 shared publication
  • С Бекметова

    Республиканский Специализированный Научно-Практический Медицинский Центр Кардиологии

    1 shared publication

Latest Publications

  • Open Access

    Влияние фиксированной комбинированной терапии телмисартаном/амлодипином на кардиометаболические риски у пациентов с артериальной гипертензией

    by М Атоева, Г Абдуллаева, Г Хамидуллаева, С Бекметова, Х Юсупова, В Мансурова

    Aim. To evaluate the antihypertensive efficacy, effects on cardiometabolic risk factors, regression of target organ damage, and safety of 6-month fixed-combination therapy with telmisartan/amlodipine in patients with arterial hypertension (AH).Materials and Methods. The study enrolled 52 patients aged 18–65 years (mean age 51.90±13.84 years) with grade I–II AH according to the ESH 2023 classification. All patients received a fixed combination of telmisartan/amlodipine Assessment was performed at baseline and after 6 months, including office blood pressure measurement, echocardiography, applanation tonometry, duplex scanning of the carotid arteries, and evaluation of glucose, lipids, uric acid, hepatic transaminases, creatinine with calculation of glomerular filtration rate (GFR), and microalbuminuria (MAU) in morning urine.Results. After 6 months of fixed-combination telmisartan/amlodipine therapy, systolic blood pressure (SBP) decreased by 19.54% and diastolic blood pressure (DBP) by 16.67% (p<0.001). Significant regression of left ventricular hypertrophy (LVH) was observed, as indicated by a 7.6% reduction in left ventricular mass index (LVMI) (p<0.001). Pulse wave velocity (PWV) decreased significantly from 9.95±2.13 m/s to 9.00±1.12 m/s (p=0.019). The lipid profile improved during therapy, with reductions in total cholesterol (p=0.009) and LDL cholesterol (p=0.018).Conclusion. Six-month fixed-combination therapy with telmisartan/amlodipine demonstrated high antihypertensive efficacy, pronounced cardio-, vaso-, and nephroprotective effects, as well as a favorable impact on the metabolic profile in patients with AH, establishing it as a combination of choice, particularly in the presence of cardiometabolic risk factors.

  • Open Access

    Antigipertenziv preparatlarning kognitiv funksiyalarga ta’siri

    by Munisa Atoeva, Guzal Abdullaeva, Xafiza Yusupova, Iroda Ibragimova

    According to the World Health Organization data, 1.13 billion people worldwide suffer from arterial hypertension, with only 21% under proper control. Dementia currently negatively affects the quality of life of 55 million people worldwide, with one new case recorded every 3.2 seconds. Analyzing the effects of antihypertensive medications on cognitive function and evaluating protective mechanisms against dementia development is currently considered one of the urgent issues. There is reliable evidence that the effects of antihypertensive medications on cognitive function are related not only to blood pressure reduction but also to independent neuroprotective mechanisms. Angiotensin receptor blockers reduce dementia risk by 12-26% compared to other antihypertensive medications. Calcium channel blockers demonstrate 17% greater neuroprotective effects compared to other drug classes. ARBs and calcium channel blockers possess the best neuroprotective properties and are considered preferable for cognitive function protection. These effects occur independently of blood pressure reduction mechanisms.